Assessing uniQure (QURE) Valuation After New Securities Fraud Lawsuit On AMT-130 Disclosures

Simply Wall St.02-12

AdvertisementWhy the new lawsuit matters for uniQure stock A fresh securities fraud class action against uniQure (NasdaqGS:QURE) is putting a spotlight on how the company previously described AMT-130’...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2610365964?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-02-12 04:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610365964","market":"us","top_or_hot":-1,"title":"Assessing uniQure (QURE) Valuation After New Securities Fraud Lawsuit On AMT-130 Disclosures","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy the new lawsuit matters for uniQure stock A fresh securities fraud class action against uniQure (NasdaqGS:QURE) is putting a spotlight on how the company previously described AMT-130’...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/assessing-uniqure-qure-valuation-after-new-securities-fraud\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing uniQure (QURE) Valuation After New Securities Fraud Lawsuit On AMT-130 Disclosures</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing uniQure (QURE) Valuation After New Securities Fraud Lawsuit On AMT-130 Disclosures\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-12 04:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/assessing-uniqure-qure-valuation-after-new-securities-fraud><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy the new lawsuit matters for uniQure stock A fresh securities fraud class action against uniQure (NasdaqGS:QURE) is putting a spotlight on how the company previously described AMT-130’...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/assessing-uniqure-qure-valuation-after-new-securities-fraud\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/assessing-uniqure-qure-valuation-after-new-securities-fraud","article_id":"2610365964","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/assessing-uniqure-qure-valuation-after-new-securities-fraud","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610365964","pubTimestamp":1770841688,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why the new lawsuit matters for uniQure stock\nA fresh securities fraud class action against uniQure (NasdaqGS:QURE) is putting a spotlight on how the company previously described AMT-130’s pivotal Huntington’s disease data and its interactions with the FDA.\nThe complaint challenges earlier messaging around biomarker results, comparisons with the ENROLL HD dataset, and the timeline for a potential Biologics License Application, which together influence how investors assess uniQure’s regulatory...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","AMT":"美国电塔","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4139":"生物科技","BK4554":"元宇宙及AR概念","BK4219":"电信塔房地产信托","BK4581":"高盛持仓","BK4084":"特种房地产投资信托","QURE":"uniQure N.V.","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"在针对AMT-130披露的新证券欺诈诉讼后评估uniQure(QURE)估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QURE":1.5,"AMT":1.5},"content_text":"AdvertisementWhy the new lawsuit matters for uniQure stock A fresh securities fraud class action against uniQure (NasdaqGS:QURE) is putting a spotlight on how the company previously described AMT-130’s pivotal Huntington’s disease data and its interactions with the FDA. The complaint challenges earlier messaging around biomarker results, comparisons with the ENROLL HD dataset, and the timeline for a potential Biologics License Application, which together influence how investors assess uniQure’s regulatory and commercial path. See our latest analysis for uniQure. The new lawsuit comes after a busy few days for uniQure, which also shared fresh AMT-191 data and presented at the WORLDSymposium. Over the same period, the share price has declined, with a 5.14% 1-day and 11.12% 7-day share price return. The 1-year total shareholder return of 87.77% contrasts with a weaker 3-year total shareholder return of 20.07% and a 5-year total shareholder return of a 32.50% loss, indicating that long-term holders have experienced a mixed journey as recent momentum has faded. If legal risk around AMT-130 has you reassessing gene therapy exposure, it could be worth widening your watchlist, using 27 healthcare AI stocks as a starting point for new ideas. With uniQure trading at US$24.71 and sitting at a very large discount to the consensus price target, yet carrying fresh legal and clinical uncertainties, is the stock being overly punished, or is the market already pricing in potential future developments? Most Popular Narrative: 55% Undervalued At a last close of $24.71 versus a widely followed fair value estimate of about $54.42, the current price sits well below that narrative anchor and puts a lot of weight on how you view uniQure’s Huntington’s and broader gene therapy pipeline.  The potential accelerated approval for AMT-130 in treating Huntington's disease could significantly boost future revenues as it would be one of the first disease-modifying treatments available for this condition. Expansion of the clinical pipeline with new studies in refractory temporal lobe epilepsy, Fabry disease, and SOD1-ALS could lead to additional revenue streams if these treatments are successful and commercialized.  Read the complete narrative. Want to see what kind of revenue curve and profit profile would need to sit behind a fair value more than double today’s price? The most followed narrative leans on rapid top line expansion, a marked shift in margins, and a future earnings multiple more often associated with mature industry leaders rather than loss making developers. Curious which specific assumptions have to line up for that story to hold? Result: Fair Value of $54.42 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, that story depends heavily on AMT-130’s regulatory outcome, as well as resolving revenue and manufacturing uncertainties that, if they break the wrong way, could quickly reset expectations. Find out about the key risks to this uniQure narrative. Another View: What the P/B Ratio Is Saying The fair value narrative leans heavily on future earnings, but today the market is also signaling something through the P/B ratio. uniQure trades at about 6.7x book value versus 2.8x for the wider US biotech group and roughly 12.8x across closer peers. That gap suggests investors are paying more than the sector average for each dollar of net assets, yet less than the peer set, which can cut both ways. If sentiment cools, there is room for the P/B to drift toward the industry level. If the story firms up, it could instead move closer to peers. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:QURE P/B Ratio as at Feb 2026 Build Your Own uniQure Narrative If you are not fully aligned with this view or prefer to work through the numbers yourself, you can build a tailored thesis in just a few minutes, starting with Do it your way. A great starting point for your uniQure research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision. Looking for more investment ideas? If this story has sharpened your focus, do not stop here. The next idea on your radar could be identified before the market pays closer attention.  Target reliable income by reviewing 14 dividend fortresses to help anchor your portfolio with higher yielding names. Hunt for mispriced opportunities through 51 high quality undervalued stocks that combine quality fundamentals with more modest expectations. Prioritise capital preservation by scanning 83 resilient stocks with low risk scores designed to highlight companies with fewer red flags.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if uniQure might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610365964","isCrawlerRequest":true}